The effect of Plasma Rich in Growth Factors (PRGF) on the treatment of an infected socket following tooth extraction

niversity of Bristol0 个研究点目标入组 40 人开始时间: 2014年12月4日最近更新: 2019年11月4日

适应症

试验速览

•1. Consent Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form
•2. Age Aged at least 18 years
•3. Compliance Understands and is willing, able and likely to comply with all study procedures and restrictions
•4. General Health Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical history or oral examination
•5. Oral Cavity Have a dry socket following tooth extraction as determined by clinical assessment

•1. Breast-feeding Women who are breast–feeding.
•2. Disease
•2.1. Current or recurrent disease/dental pathology that could affect the assessments.
•2.2. Bleeding disorders.
•2.3. Immuno-compromised.
•2.4. Current or relevant previous history of serious, severe or unstable physical or psychiatric illness, or any medical disorder that may require treatment or make the participant unlikely to fully complete the study, or any condition that presents undue risk from the study products or procedures.
•3. Allergy/Intolerance Known or suspected intolerance or sensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
•4. Medication- Any medication which in the Investigators opinion may interfere with the study
•5. Clinical Study/Experimental Medication-Participation in another clinical study or receipt of an investigational drug within 10 days of the screening visit.
•6. Substance abuse Recent history of alcohol or other substance abuse.
•7. Personnel A member of the study site or a family relative. The study site for this protocol is the Clinical Trials Unit in the Bristol Dental School and Hospital. Employees of the Bristol Dental School and Hospital not associated with the Clinical Trials Unit are eligible to participate.
•8. Any patient who, in the judgement of the investigator, should not participate in the study.

发起方

niversity of Bristol